Paul Audhya Sells 2,239 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

Posted by George Bondi on May 29th, 2026

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) insider Paul Audhya sold 2,239 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $59,960.42. Following the transaction, the insider directly owned 150,260 shares of the company’s stock, valued at $4,023,962.80. The trade was a 1.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ KALV opened at $26.77 on Friday. KalVista Pharmaceuticals, Inc. has a 12 month low of $9.83 and a 12 month high of $26.85. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12. The business has a 50-day moving average of $22.14 and a 200-day moving average of $17.76.

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million during the quarter, compared to the consensus estimate of $39.03 million. Sell-side analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on KALV. Citizens Jmp downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. JonesTrading downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. Stifel Nicolaus boosted their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. HC Wainwright downgraded KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $37.00 to $27.00 in a research report on Friday, May 1st. Finally, Needham & Company LLC downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $30.60.

Read Our Latest Research Report on KalVista Pharmaceuticals

Institutional Trading of KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of KALV. Tudor Investment Corp ET AL bought a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $24,360,000. Jefferies Financial Group Inc. bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $3,494,000. Blue Owl Capital Holdings LP bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at about $1,522,000. Hennion & Walsh Asset Management Inc. boosted its stake in shares of KalVista Pharmaceuticals by 93.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after purchasing an additional 165,236 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its stake in shares of KalVista Pharmaceuticals by 391.9% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after purchasing an additional 160,128 shares in the last quarter.

About KalVista Pharmaceuticals

(Get Free Report)

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.